2010 New Antimicrobial Drug Discovery and Development Gordon Research Conference

2010新型抗菌药物发现与开发戈登研究会议

• 批准号: 7906349
• 负责人: George Louis Drusano
• 金额: $ 1.5万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7906349
• 关键词: Academia; Accident and Emergency department; Acinetobacter; Antibiotics; Carbapenems; Colistin; Communities; Development; Enzymes; Escherichia coli; Eye; Hearing; Industry; Infection; Intensive Care Units; International; Klebsiella; Lactamase; Licensing; Macrolides; Measures; Monobactams; Organism; Postdoctoral Fellow; Predisposition; Prevalence; Process; Pseudomonas aeruginosa; Research; Resistance; Resistance profile; Science; Scientist; Site; Staphylococcus aureus; Streptococcus pneumoniae; Structure; Therapeutic Intervention; United States; Voice; antimicrobial; antimicrobial drug; drug discovery; meetings; member; methicillin resistant Staphylococcus aureus; pathogen; symposium

DESCRIPTION (provided by applicant): This Gordon Conference is aimed at a serious national and international problem: the lack of new antimicrobial agents for multi-resistant infections. In both the Intensive Care Unit (ICU) and the Community, organisms that commonly cause serious infections have become resistant to many of our most effective antibiotics. In the Community, organisms such as Streptococcus pneumonia have a rate of non- susceptibility to ¿-lactam antibiotics exceeding 20%. Other effective agents, such as macrolides, have resistance rates on the order of 40%. Community-Acquired MRSA has exploded in prevalence across the United States and is commonly seen in Emergency Departments. In the ICU, MRSA makes up approximately 50% of all Staphylococcus aureus infections and we have seen the advent of multi- resistant Gram-negative organisms, so that even common pathogens such as Klebsiella and E. coli may carry extended-spectrum ¿-lactamases, rendering them resistant to many of our best agents and, in the case of K-pc enzymes, this resistance profile includes carbapenems. In the case of Pseudomonas aeruginosa and Acinetobacter species, it is now reasonably common for an infecting pathogen to be resistant to all licensed antibiotics. A measure of our desperation is that we have resurrected 50 year-old, relatively toxic agents (colistin/polymixins) to have at least one available therapeutic intervention. In this Conference, we have a unique cross-disciplinary approach to the problem, where chemists, basic biologists and translational scientists meet and where Industry, Academia, Regulatory Agencies and political observers are all stakeholders and are invited to contribute to the interchange. Our past meetings have been scientifically rigorous and open, with both new science coming forward and the identification of bottlenecks in the process being part of the process. We have a conference where we are dedicated to the broadest participation and, in specific, are desirous of inclusion of younger members of the field at the post-doctoral level, to bring fresh perspective to the problems being examined. The site is well-suited for this interchange and the structure of the Conference follows the classical Gordon Conference format. The Discussion Leaders have been chosen with an eye toward generating robust, insightful discussion after the presentations. The format is democratic so that all voices will be heard and the emphasis will be on presenting the best and newest science and asking the correct questions to push the field forward. In this proposal, we ask for supplementary support for this important undertaking.

描述（由申请人提供）：本次戈登会议旨在解决一个严重的国内和国际问题：缺乏新的抗多重耐药感染药物。在重症监护病房（ICU）和社区，通常引起严重感染的微生物已经对我们许多最有效的抗生素产生了耐药性。在欧共体，肺炎链球菌等生物对内酰胺类抗生素不敏感的比率超过20%。其他有效的药物，如大环内酯类药物，耐药率约为40%。社区获得性耐甲氧西林金黄色葡萄球菌在美国的流行率呈爆炸式增长，常见于急诊科。在ICU， MRSA约占所有金黄色葡萄球菌感染的50%，我们已经看到了多重耐药革兰氏阴性菌的出现，因此即使是常见的病原体，如克雷伯氏菌和大肠杆菌，也可能携带广谱内酰胺酶，使它们对我们的许多最好的药物产生耐药性，在K-pc酶的情况下，这种耐药性包括碳青霉烯类。就铜绿假单胞菌和不动杆菌而言，现在一种感染病原体对所有许可的抗生素都具有耐药性是相当普遍的。我们已经复活了50年的，相对有毒的药物（粘菌素/多粘菌素），至少有一种可用的治疗干预措施，这可以衡量我们的绝望。